Quantitative assessment of myelin density using $[^{11}C]$MeDAS PET in patients with multiple sclerosis: a first-in-human study

Chris W. J. van der Weijden1 · Jan F. Meilof2,3 · Anouk van der Hoorn4 · Junqing Zhu5 · Chunying Wu5 · Yanming Wang6 · Antoon T. M. Willemsen1 · Rudi A. J. O. Dierckx1 · Adriaan A. Lammertsma1 · Erik F. J. de Vries1

Received: 14 October 2021 / Accepted: 19 March 2022 / Published online: 2 April 2022
© The Author(s) 2022

Abstract
Purpose Multiple sclerosis (MS) is a disease characterized by inflammatory demyelinated lesions. New treatment strategies are being developed to stimulate myelin repair. Quantitative myelin imaging could facilitate these developments. This first-in-man study aimed to evaluate $[^{11}C]$MeDAS as a PET tracer for myelin imaging in humans.

Methods Six healthy controls and 11 MS patients underwent MRI and dynamic $[^{11}C]$MeDAS PET scanning with arterial sampling. Lesion detection and classification were performed on MRI. $[^{11}C]$MeDAS time-activity curves of brain regions and MS lesions were fitted with various compartment models for the identification of the best model to describe $[^{11}C]$MeDAS kinetics. Several simplified methods were compared to the optimal compartment model.

Results Visual analysis of the fits of $[^{11}C]$MeDAS time-activity curves showed no preference for irreversible (2T3k) or reversible (2T4k) two-tissue compartment model. Both volume of distribution and binding potential estimates showed a high degree of variability. As this was not the case for 2T3k-derived net influx rate ($K_i$), the 2T3k model was selected as the model of choice. Simplified methods, such as SUV and MLAIR2 correlated well with 2T3k-derived $K_i$, but SUV showed subject-dependent bias when compared to 2T3k. Both the 2T3k model and the simplified methods were able to differentiate not only between gray and white matter, but also between lesions with different myelin densities.

Conclusion $[^{11}C]$MeDAS PET can be used for quantification of myelin density in MS patients and is able to distinguish differences in myelin density within MS lesions. The 2T3k model is the optimal compartment model and MLAIR2 is the best simplified method for quantification.

Trial registration.
NL7262. Registered 18 September 2018.

Keywords Multiple sclerosis · Quantitative myelin imaging · Positron emission tomography · Arterial input function · Demyelination

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| 1T2k | Reversible 1 tissue compartment model |
| 2T3k | Irreversible 2 tissue compartment model |
| 2T4k | Reversible 2 tissue compartment model |
| AIC | Akaike information criterion |
| BH | Black hole |
| BPND | Binding potential |
| DM | Demyelinated lesion |
| GM | Gray matter |

This article is part of the Topical Collection on Neurology.

© Springer
**Introduction**

Multiple sclerosis (MS) is the most common neurodegenerative disease among young adults. MS is characterized by focal inflammation, which results in demyelinated and neurodegenerative plaques, called lesions [1, 2]. The myelin sheaths around neuronal axons have neuroprotective, axonal metabolic, and neurotransmission support functions [3, 4]. Disturbances in myelin integrity therefore decrease neuronal efficacy and make neurons susceptible to degeneration. Restoration of the myelin sheath would restore neuronal function and promote neuronal survival. This hypothesis has prompted the search for remyelination therapies. However, at present, an accurate biomarker to evaluate the efficacy of such remyelination strategies is missing.

In vivo characterization of myelin density using imaging techniques would be an attractive way for monitoring remyelination therapies, as it enables direct insight in their efficacy. Several magnetic resonance imaging (MRI) techniques for myelin imaging have been developed. Unfortunately, a recent review of these methods concluded that current myelin MRI methods do not have the accuracy required for quantitative monitoring of myelin repair [5]. Another technique that could potentially be used for myelin imaging is positron emission tomography (PET) enabling quantification using specific radiopharmaceuticals [6–9].

The disease process in MS involves inflammation resulting in myelin loss and possibly direct neurodegeneration. Some PET tracers for neuroinflammation have been tested in MS [4, 10, 11]. At present, there are no PET tracers that selectively bind to myelin. However, it has been established that several tracers, originally developed for imaging amyloid, also bind to the beta-pleated sheet structure in myelin. This actually explains the relatively high white matter uptake of [11C]PiB in healthy volunteers. As there is no clinical overlap between neurodegenerative diseases associated with amyloid deposition and multiple sclerosis, these tracers are of potential interest for myelin imaging. Several amyloid tracers have been used to depict myelin content in preclinical studies. [11C]PiB PET was able to detect demyelination in a primate model of MS, although [11C]PiB uptake only moderately correlated with myelin histology [12]. Yet, [11C]PiB and its derivatives have recently been used in small clinical studies in MS [6, 7, 13].

Although [11C]PiB is already available clinically, as it is already used in the diagnosis of Alzheimer’s disease, animal studies have shown that [11C]MeDAS PET might be more accurate for imaging myelin than [11C]PiB [6]. Aside from [11C]PiB’s affinity for amyloid-beta depositions, [11C]PiB is proposed to bind to the beta sheets of the myelin basic protein (MBP). However, [11C]MeDAS has actually been shown to bind to intact MBP, which is a key component of intact myelin [14, 15]. Upon myelin damage, MBP loses its compact structure, resulting in the destruction of the binding site for [11C]MeDAS. Therefore, a reduction in [11C]MeDAS PET signal is indicative for a reduction in myelin density. To date, however, [11C]MeDAS PET has not been used in humans yet.

Therefore, the purpose of this study was to (1) assess whether [11C]MeDAS PET can detect differences in myelin density in the human brain and to (2) determine the best method for quantitatively analyzing [11C]MeDAS PET data.

**Methods**

**Autoradiography**

Post-mortem brain tissues of a MS patient in 10% formalin obtained from University Hospitals, Cleveland Medical Center, were cryoprotected sequentially in 10%, 20%, and 30% sucrose. Brain tissues were placed in optimal cutting temperature (O.C.T.) embedding medium and frozen at −20 °C. Next, brain tissues were sectioned at 20 µm in a cryostat and mounted directly onto Superfrost Plus microscope slides (Fisher Scientific, Hampton, USA). These brain sections were incubated in [11C]MeDAS (specific activity of 238,650 MBq/µmol, 10% ethanol in saline, 1295 MBq/mL) for 20 min. The slides were then quickly washed with PBS buffer (10 mM, pH 7.0) 3 times. After being dried by air, the slides were put in a cassette and exposed to film for 10 min. In the meantime, standard Luxol Fast Blue (LFB) staining was performed on adjacent brain tissues.

**Subjects**

Eleven MS patients, diagnosed according to the revised McDonald criteria [16], and 6 healthy volunteers (HC) were
included in this prospective study. The inclusion criteria were at least 18 years old and, in case of MS, a diagnosis of progressive MS. The following exclusion criteria were applied: pregnancy or breastfeeding; a previous adverse reaction to gadolinium; claustrophobia; a diagnosis of cerebrovascular disease; a clinical history of diminished renal or liver function; participation in a trial and use of investigational medication at the time of the study; the presence of magnetizable materials in the body. Written informed consent was obtained from all study participants. The study was approved by the Medical Ethics Review Committee of the University Medical Center Groningen, METc no. 2018/450, Netherlands, Trial register: Trial NL7262.

Data acquisition

All participants underwent arterial cannulation of either the radial or ulnar artery in the wrist and a 60-min dynamic \([^{11}C]MeDAS\) PET acquisition with arterial blood sampling. \([^{11}C]MeDAS\) PET scans were acquired on a Siemens Bio-graph Vision PET/CT scanner, starting with a low-dose CT for attenuation correction, followed by the \([^{11}C]MeDAS\) PET scan, which was acquired in list mode. Individual doses of \([^{11}C]MeDAS\) were prepared on site according to GMP quality assurance criteria. \([^{11}C]MeDAS\) was injected simultaneously with the start of the 60-min PET scan. The total dose in the injection syringe was 416 ± 90 MBq for HC and 498 ± 87 MBq for MS patients. After measuring the amount of tracer that remained in syringe and tubing, the net injected dose was calculated to be 203 ± 46 MBq for HC and 209 ± 35 for MS patients. Continuous arterial blood sampling was performed with an online detection system at a rate of 5 mL/min for 5 min, followed by a rate of 1.66 mL/min for the remainder of the scan. In addition, 5 manual arterial blood samples of 5 mL each were collected at 10, 20, 30, 45, and 60 min for calibrating the whole blood curve and measuring plasma to whole blood ratios. Furthermore, the manual blood samples were used to calculate percentage of intact tracer, which was subsequently fitted with a hill function in order to generate a metabolite-corrected arterial plasma input function.

PET images were corrected for randoms, dead-time, scatter, decay, and attenuation and reconstructed in 26 frames (1 × 10, 10 × 5, 1 × 10, 2 × 30, 3 × 60, 2 × 150, 4 × 300, and 3 × 600 s) with a voxel size of 0.9 × 0.9 × 0.9. MRI scans were performed on the same day as the PET scan. All MRI scans were acquired on the same 3.0 Tesla scanner (Siemens Magnetom Prisma) equipped with a 64-channel head coil. The imaging protocol included the following sequences: a sagittal 3D T1w MPRAGE (TR: 2300 ms; TE: 2.31 ms; TI: 900 ms; flip angle: 8°; slice thickness: 0.9 mm; voxel size: 0.9 × 0.9 × 0.9 mm), a sagittal 3D T2w-FLAIR (TR: 5000 ms; TE: 392 ms; TI: 1800 ms; flip angle: 90°, slice thickness: 0.9 mm; voxel size: 0.9 × 0.9 × 0.9 mm), a sagittal 3D T2w (TR: 3200 ms; TE: 408 ms; flip angle: 90°; slice thickness: 0.9 mm; voxel size: 0.9 × 0.9 × 0.9 mm), and a post-gadolinium sagittal 3D T1w MPRAGE with parameters identical to those of pre-contrast 3D T1w.

Data analysis

Lesions (Fig. 1) were radiologically identified and classified using T1w, T2w, T2w-FLAIR, and T1w post-contrast MRI. When lesions were hyperintense on T1w post-contrast MRI, they were classified as active lesions [17]. Furthermore, lesions were characterized based on their expected myelin density (Fig. 2), as validated using histopathological data by Barkhof et al. [18, 19], and for black holes based in the study of Sahraian et al. [18]. T2w and T2w-FLAIR hyperintense lesions that were iso-intense to normal-appearing
white matter (NAWM) on T1w were classified as remyelinated lesions; hypointense T1w lesions that had a smaller lesion volume on T1w compared with T2w and T2w-FLAIR were classified as partial myelinated lesions; hypointense T1w lesions of the same volume as on T2w and T2w-FLAIR images were classified as fully demyelinated lesions; and iso-intense T1w lesions compared with CSF were called black holes and classified as demyelinated and neurodegenerative lesions. Only lesions with at least one diameter larger than 3 mm were considered in this study.

Tissue segmentation was performed to derive binary masks representing white matter lesions (WML), perilesions, contra-lateral NAWM, white matter (WM), and gray matter (GM). PMOD (v4.1, PMOD Technologies, Zurich, Switzerland) was used for manual segmentation of WML, peri-lesions, and contra-lateral NAWM. Manual segmentation of WML was performed using the T2w-FLAIR MRI scan. Subsequently, contralateral NAWM regions were generated by assessing the absence of any structural damage using T1w and T2w-FLAIR. Peri-lesions were generated by applying lesion growing of 3 voxels and subsequently subtracting the WML. GM and WM volumes of interest (VOIs) were generated by performing T1w segmentation using SPM12 with a threshold of $\geq 0.9$ [20]. A total NAWM volume of interest (VOI) was acquired by extracting the segmented lesion VOIs from the WM VOI.

Within the PMOD software package (v4.1), $[^{11}\text{C}]$ MeDAS PET images were corrected for movement and co-registered to the T1-weighted MRI using rigid matching. Movement of $<5$ mm was considered to be minimal for which no motion correction was performed, but movement between $>5$ mm in any direction was subjected to motion correction. Scan motion was determined to be $<10$ mm for all subjects. Subsequently, time-activity curves (TACs) in anatomically delineated VOIs based on the Hammers brain atlas [21] were generated. These VOIs were aggregated into frontal lobe, temporal lobe, occipital lobe, parietal lobe, and basal ganglia according to their anatomical location. These VOIs, together with the cerebellum, corpus callosum, thalamus, and brainstem derived from the Hammers atlas, were subdivided between gray matter (GM) and white matter (WM), and between left and right, where applicable. Using these VOI TACs (total 26) and the whole blood and metabolite-corrected plasma curves, $[^{11}\text{C}]$MeDAS kinetic

Fig. 2  Lesion classification system based on myelin density
analysis was performed, investigating the reversible 1-tissue compartment model (1T2k) and the irreversible (2T3k) and reversible (2T4k) 2-tissue compartment models, all including a parameter for fractional blood volume (V_B).

Subsequently, the efficacy of several graphical methods (Patlak graphical analysis, MLAIR1 and MLAIR2) was investigated by comparing the net influx rate (K_i) estimates with K_i estimates derived from the 2T3k model using the same VOIs for all methods. Patlak graphical analysis is susceptible to bias due to noisy data and requires the determination of the time interval until equilibrium is reached to select the data points for linear regression. For MLAIR, on the other hand, all data points are used for K_i estimations [22]. Consequently, MLAIR is less prone to bias than Patlak analysis. Nonetheless, MLAIR2 remains somewhat susceptible to noise and therefore performs better on a VOI level than on a voxel level. Because MLAIR2 directly calculates K_i from the multiple linear regression, these estimates should be stable and robust even at a voxel level. A more detailed description and the exact formulas of Patlak graphical analysis, MLAIR1, and MLAIR2 can be found in the article by Kim and colleagues [22]. In addition, standardized uptake values (SUV) were calculated for the intervals 40–50 min and 50–60 min by correcting tissue uptake for net injected dose and body weight. Next, these SUV were compared with K_i to assess whether SUV, which can be derived from a static scan, would be accurate enough in lesion differentiation to substitute kinetic analyses. Finally, [11C]MeDAS PET lesion quantification was performed using both compartment models and simplified methods.

Statistical analysis

The Akaike information criterion (AIC) was used to determine the optimal compartment model for describing [11C]MeDAS kinetics across the VOIs derived from the Hammers atlas and subsequently for WML. The model with the highest frequency of lowest AIC per VOI was selected as the preferred model. The correspondence of kinetic parameters with graphical methods and SUV was investigated using Pearson correlation analysis. Next, both kinetic parameters and SUV were assessed on their ability to differentiate between GM and WM using parametric tests, where applicable. Subsequently, the ability of the various parameters to differentiate between lesions that were radiologically characterized into different myelin densities was compared with NAWM using the Mann–Whitney U test. Compartment modeling produced parameter estimates with a percent standard error (SE) for each individual brain region in each subject (PMOD v4.1). BP_ND, V_T, and K_i estimates for a particular brain region in an individual subject with %SE exceeding an arbitrary threshold of 25% were considered unreliable and omitted from further analysis.

Prior to analysis, normality was assessed according to Kolmogorov–Smirnov, using a p < 0.05 for non-normal distributed data. When applicable, equal variance was assumed according to Levene’s test for equality of variance, using a p < 0.05 for lack of equal variances. All statistical analyses were performed in SPSS and differences were considered to be significant at p < 0.05.

Results

Autoradiographic characterization of [11C]MeDAS binding to post-mortem tissue

In preparation for the first-in-human clinical trial, the binding of [11C]MeDAS to myelin was characterized by film autoradiography in sections of fresh-frozen post-mortem tissue of a patient with extensive demyelination in the brain (Fig. 3A–C). These autoradiograms showed a heterogeneous distribution of [11C]MeDAS uptake, which corresponded with the myelin density in the brain (Fig. 3D–E, H). A high density of binding sites was detected in heavily myelinated white matter regions (189 ± 11; n = 6) with much less binding of [11C]MeDAS in the less densely myelinated cortical gray matter regions (111 ± 19; n = 6) and lesions (75 ± 58; n = 6). This distribution pattern of [11C] MeDAS was identical to the staining of adjacent sections using Luxol Fast Blue (LFB) (Fig. 3F–G), suggesting that [11C]MeDAS binds to myelin in the brain. Consequently, the binding of [11C]MeDAS decreased significantly in demyelinated regions, which corresponded with LFB staining results.

Subjects

Six HC and eleven MS patients were recruited in this study. For one MS patient, radiolabeled metabolites could not be measured due to HPLC malfunction and in another MS patient, the arterial cannula required for blood sampling could not be placed. This resulted in 9 evaluable MS patients, of which 5 had primary and 4 had secondary progressive MS. The 9 MS patients had a mean age of 51.8 (± 4.9) and no visible cerebral lesions on MRI. No significant differences were observed between HC and MS with respect to age and sex. Within MS patients, a total of 292 lesions (average 32 ± 28 lesions/patient) were identified, covering a total volume of 63 ml. No lesions were hyperintense on T1w post gadolinium MRI scans, and therefore, all lesions were classified as inactive lesions.
played in Supplementary Fig. 1. WM washout was much slower than GM washout, suggesting autoradiograms showing a significant decrease of metabolite analysis (Fig. 4) showed fast metabolism of [11C]MeDAS in blood and tissue Metabolite analysis (Fig. 4) showed fast metabolism of [11C]MeDAS with only 19.4 ± 6.9% of intact tracer left after 10 min, which eventually stabilized around 5%. In addition, high influx of tracer was observed in white matter with a gradual washout (Fig. 4). As expected, for whole brain WM, influx of tracer was less than the GM. More importantly, WM washout was much slower than GM washout, suggestive for myelin-mediated tracer binding in WM. Individual non-metabolized plasma tracer concentration curves are displayed in Supplementary Fig. 1.

Model comparison

The fits of the 1T2k, 2T3k, and 2T4k models for whole brain GM, whole brain WM, and a lesion are displayed in Fig. 5. In general, the 1T2k model was not able to describe the kinetic behavior of the tracer, as demonstrated by the sum of squared residuals (Supplementary Table 3) and the goodness of fit ($R^2$; Supplementary Table 4). In contrast, both 2T3k and 2T4k models performed well. The individual rate constant estimates and standard errors obtained with these models are summarized in Supplementary Tables 5 and 6, respectively.

Using AIC, the frequency of model preference per region derived from the Hammers atlas was calculated, resulting in the 2T4k model as preferred model for [11C]MeDAS quantification (Fig. 6). However, 2T4k derived $V_T$ and $BP_{ND}$ estimates had a SE $> 25\%$ for 11.0% and 15.7% of the regions, respectively. On the other hand, for 1T2k-derived $V_T$ and for 2T3k-derived $K_2$, there were no regions with an SE $> 25\%$. Interestingly, the difference in AIC values was relatively small between 2T3k and 2T4k models. In contrast to the 2T3k model, the 2T4k model resulted in a large percentage of microparameter estimates with a SE $> 25\%$, in particular k3 and k4 (Supplementary Tables 7, 8, 9, and 10), which may explain the poorer identifiability of 2T4k-derived $V_T$ and $BP_{ND}$.

For white matter lesions (WML), the 2T3k model showed the highest preference frequency (Fig. 6). Both 2T3k (29.7% for $K_I$) and 2T4k (53.2% for $V_T$ and 86.3% for $BP_{ND}$) had a high number of lesions (Table 1) with inaccurate estimates (SE $> 25\%$). Fixing $V_B$ at 0.02 (which is the mean $V_B$ of white matter [23]) and/or $K_1/k_2$ ratio to the whole brain WM value resulted in a reduction in uncertain estimates (i.e., lower SE) for the 2T3k model but did not have much impact on the uncertainty of 2T4k-derived $V_T$ and $BP_{ND}$ estimates. Furthermore, 2T3k $K_I$ estimates (when fixing either $K_1/k_2$ to the whole brain WM value or both $K_1/k_2$ and $V_B$) showed high correlations (Table 2) with the original (no parameters fixed) 2T3k $K_I$ estimates ($r = 0.95$, slope = 1.04; $r = 0.93$, slope = 1.02, respectively). Based on these findings, the 2T3k model with both $K_1/k_2$ fixed to the whole brain WM value and either $V_B$ fixed to 0.02 or free $V_B$ was used for WML quantification.

Simplified quantification methods

The performance of Patlak graphical analysis, MLAIR1, and MLAIR2 was assessed by correlating their $K_I$ estimates with those derived from the 2T3k model (Table 3; Fig. 7). All three graphical methods produced $K_I$ values that correlated well with 2T3k-derived $K_I$ (Patlak $r = 0.87$, MLAIR1 $r = 0.99$, and MLAIR2 $r = 0.99$). In addition, the SUV values from 40 to 50 min and from 50 to 60 min were evaluated (Supplementary Tables 1 and 2). Strong correlations were observed between SUV estimates and 2T3k-derived $K_I$ ($r = 0.83$ for SUV from 40 to 50 min and $r = 0.86$ for SUV from 50 to 60 min), but subject-dependent bias when compared to 2T3k $K_I$ was observed. Among the simplified methods, only Patlak $K_I$ showed a slightly poorer correlation with 2T3k $K_I$ in MS patients than in HC. This might be due to [11C]MeDAS kinetics being better described by multiple linear regression than a single linear regression, as variations in fitting start time did not improve the accuracy of the Patlak $K_I$. A comparison of Patlak analysis with 2T3k and Logan analysis with 2T4k can be found in Supplementary Fig. 2.

Additional qualitative assessment of the simplified methods showed that both Patlak and MLAIR1 produced very noisy images (Fig. 8). Therefore, only SUV 40–50 min, SUV 50–60 min, and MLAIR2 were considered for further assessment.

Differential analysis between GM and WM

To determine which quantitative analysis methods and estimated parameters can distinguish between whole brain GM and whole brain WM, quantitative measurements illustrative for tracer binding were assessed in HC. $K_I$ derived from the 2T3k model and MLAIR2 and SUV of 40–50 min and SUV of 50–60 min were all able to differentiate between GM and WM (Table 4).
Lesion analysis

When lesions were classified based on myelin density (Fig. 2; Table 5), 105 lesions were identified as black holes (BH), 111 as demyelinated lesions (DM), 69 as partial myelinated lesions (PM), and 7 as remyelinated lesions (RM). Quantitative PET outcome parameters were assessed for their ability to differentiate lesions from NAWM. Outcome parameters from the 2T3k models were estimated, using $K_1/k_2$ fixed to the $K_1/k_2$ value of whole brain WM and either free $V_B$ or $V_B$ fixed to 0.02. In addition, MLAIR2, SUV 40–50 min, and SUV 50–60 min were also investigated. When comparing parameters in lesions with those in contra-lateral NAWM (Table 6), all models showed significant differences for black holes, demyelinated lesions, and partial myelinated lesions, but not for remyelinated lesions. The absence of significant differences between remyelinated lesions and NAWM might be because myelin density is largely restored in these lesions.
Fig. 5 Representative model fits of A whole brain GM, B whole brain WM, and C an MS lesion using 1T2k, 2T3k, and 2T4k models.
Fig. 6 Model preference according to the Akaike information criterion for A GM regions, B WM regions, and C MS lesions. HC, healthy control, MS, multiple sclerosis, GM, gray matter, WM, white matter, BH, black holes, DM, demyelinated lesions, PM, partial myelinated lesions, RM, remyelinated lesions.
Discussion

Accurate measurements of myelin density would aid in treatment monitoring and facilitate early diagnosis and assessment of prognosis of patients with MS. Therefore, this study aimed to investigate whether $[^{11}C]$MeDAS PET could be used to measure myelin density and, if so, to determine the optimal quantification method. The preclinical autoradiographic characterization in post-mortem brain tissue showed that $[^{11}C]$MeDAS binding corresponded with myelin density. The subsequent PET study showed that $[^{11}C]$MeDAS data were best analyzed using a 2T3k model, and that fixation of the $K_1/k_2$ ratio seemed to produce robust estimates of myelin density. Furthermore, the simplified method MLAIR2 and SUV estimates correlated well with results of the 2T3k model, with MLAIR2 having the highest correlation and was also qualitatively accurate. As compared with NAWM, decreased tracer uptake was observed across lesions, except in remyelinated lesions.

Unfortunately, no patients with active lesions were included, which most likely is a result of enrolling only patients with progressive MS. The inclusion of RRMS would probably have resulted in the inclusion of more patients with active lesions, as the prevalence of active lesions is higher in RRMS than in progressive MS [24]. The inclusion of RRMS patients would probably also have resulted in a larger sample of remyelinated lesions, as this is more prevalent in RRMS. For this proof-of-concept study, however, only patients with progressive MS were enrolled, as demyelination is more prevalent in this group. In addition, the presence of active inflammatory lesions with a disturbed blood brain barrier could have introduced unwanted tracer uptake or clearance.

From animal studies, the optimal compartment model was defined as the 2T4k model [6]. Therefore, a 2T4k model was also expected to be the preferred model in humans. However, PET tracer kinetics may vary across species, and therefore, the findings regarding tracer kinetics in animals are not always directly translatable to humans. Visual inspection of the $[^{11}C]$MeDAS PET model fits showed only minor differences between the 2T3k and 2T4k models. When assessing the optimal compartment model according to AIC, the 2T4k model seemed to be the preferred model, but it provided a substantially higher number of ill-determined parameter estimates than the 1T2k and 2T3k models. Within lesions, the precision of 2T4k $V_T$ and $BP_{ND}$ estimates was also relatively low and could not be improved adequately by fixing $K_1/k_2$ and/or $V_B$. Logan graphical analysis gave similar results as the 2T4k model (Supplementary Fig. 2) but did not improve the precision of $V_T$ estimates. In contrast, the precision of 2T3k derived $K_i$ estimates improved significantly with $K_1/k_2$ fixation. The inadequacy of the 2T4k model to quantify

Table 1 Percentage of lesions with unreliable modeling estimates (SE > 25%) with or without fixing $V_B$ and/or $K_1/k_2$

|                | None | $V_B$ | $K_1/k_2$ | $K_1/k_2 + V_B$ |
|----------------|------|-------|-----------|-----------------|
| 1T2k $V_T$    | 7.8% | 6.8%  | n.a       | n.a             |
| 2T3k $K_i$    | 29.7%| 27.6% | 11.3%     | 11.9%           |
| 2T4k $V_T$    | 53.2%| 47.1% | 53.6%     | 51.5%           |
| 2T4k $BP_{ND}$| 86.3%| 81.6% | 62.5%     | 62.1%           |

* $V_T$, volume of distribution; $K_i$, net influx rate; $BP_{ND}$, binding potential; $V_B$, volume of blood fraction.

Table 2 Correlation of parameter estimates using models with fixed $V_B$ and/or $K_1/k_2$, as compared with the original models

|                   | $V_B$ | $K_1/k_2$ | $K_1/k_2 + V_B$ |
|-------------------|-------|-----------|-----------------|
| $r$                |       |           |                 |
| Slope             |       |           |                 |
| Intercept         |       |           |                 |

|                   | $V_B$ | $K_1/k_2$ | $K_1/k_2 + V_B$ |
|-------------------|-------|-----------|-----------------|
| $r$                |       |           |                 |
| Slope             |       |           |                 |
| Intercept         |       |           |                 |

|                   | $V_B$ | $K_1/k_2$ | $K_1/k_2 + V_B$ |
|-------------------|-------|-----------|-----------------|
| $r$                |       |           |                 |
| Slope             |       |           |                 |
| Intercept         |       |           |                 |

* $V_T$, volume of distribution; $K_i$, net influx rate; $BP_{ND}$, binding potential; $V_B$, volume of blood fraction.

Table 3 Correlations between $K_i$ values derived from simplified methods with those for the original 2T3k model over all brain regions

| Simplified method | Controls | MS | All subjects |
|-------------------|----------|----|--------------|
| $r$               | Slope    | Intercept | $r$ | Slope    | Intercept | $r$ | Slope    | Intercept |
| SUV 40–50 min     | 0.84     | n.a       | 0.87 | n.a     | 0.82      | n.a     | 0.85 | n.a     | 0.83      |
| SUV 50–60 min     | 0.87     | 0.70      | 0.85 | n.a     | 0.74      | n.a     | 0.86 | n.a     | 0.69      |
| Patlak Ki         | 0.97     | 0.93      | 0.80 | 0.63    | 0.00      | n.a     | 0.87 | 0.78    | 0.00      |
| MLAIR1 Ki         | 1.00     | 0.94      | 0.99 | 0.89    | 0.00      | n.a     | 0.99 | 0.91    | 0.00      |
| MLAIR2 Ki         | 1.00     | 0.95      | 0.99 | 0.90    | 0.01      | n.a     | 0.99 | 0.93    | 0.00      |

* $K_i$, net influx rate; n.a., not applicable.
myelin density within lesions could be due to the scan duration. It seems plausible that a duration of 60 min is too short for accurate estimation of the $k_4$, and therefore, a longer scan might be needed. To support this hypothesis, PET data were re-analyzed for shorter acquisition times (40 and 50 min). A reduced accuracy of the 2T4k parameters $V_T$ and $BP_{ND}$

Fig. 7 Correlation of $K_i$ from graphical methods and SUV with the $K_i$ derived from the 2T3k model. The black line is the line of identity. Each data point represents a brain region from an individual subject.
was observed for shorter scanning times (Supplementary Table 11). On the other hand, when acquisition times longer than 60 min are used, radioactivity levels may become so low that proper signal-to-noise ratios and reliable metabolite analyses are no longer guaranteed due to the short half-life of carbon-11, resulting in a reduced accuracy of parameter estimates. In contrast, shortening the acquisition time did not substantially affect the precision of the \( K_i \) estimates obtained from the 2T3k model (Supplementary Table 12). Nevertheless, shortening the acquisition time tended to

---

**Fig. 8** \([^{11}C]\)MeDAS PET images. The pink arrow indicates a MS lesion, which was hypo-intense on T1w MRI and hyper-intense on T2w-MRI. Decreased \([^{11}C]\)MeDAS uptake can be observed in MLAIR2, SUV 40–50 min, and SUV 50–60 min images, whereas the \( K_i \) images of Patlak and MLAIR1 are too noisy to clearly differentiate differences in myelin density. For the presentation purpose, the PET images were smoothed with a 4-mm Gaussian filter.

**Table 4** Differential analysis between whole brain GM and whole brain WM using HC

|                      | GM mean (± SD) | WM mean (± SD) | \( T \) | Degrees of freedom | \( p \) value |
|----------------------|---------------|----------------|--------|-------------------|--------------|
| 2T3k \( K_i \) [mL min\(^{-1}\) cm\(^{-3}\)] | 0.064 ± 0.018 | 0.113 ± 0.031 | −3.4   | 10                | 0.007        |
| MLAIR2 \( K_i \) [mL min\(^{-1}\) cm\(^{-3}\)] | 0.062 ± 0.018 | 0.111 ± 0.029 | −3.5   | 10                | 0.005        |
| SUV of 40–50 min [g cm\(^{-3}\)] | 1.71 ± 0.26  | 2.74 ± 0.44   | −4.9   | 10                | 0.001        |
| SUV of 50–60 min [g cm\(^{-3}\)] | 1.53 ± 0.24  | 2.56 ± 0.42   | −5.1   | 10                | <0.001       |
slightly increase $K_i$ estimates across all brain regions (Supplementary Table 13), but $K_i$ values obtained from 60-min acquisition data were still highly correlated with those obtained from 50 min ($r = 0.87; p < 0.001; \text{slope} = 1.01; \text{intercept} = 0.013$) and 40 min ($r = 0.87; p < 0.001; \text{slope} = 1.07; \text{intercept} = 0.015$) acquisition data. So, the present results indicate that, despite the introduction of some bias, it is possible to quantify myelin density using $K_i$ using relatively short acquisition times. Longer scans would only increase patient burden and may not necessarily improve reliability of parameter estimates, mainly because obtaining reliable labeled metabolite estimates at later time points is difficult. Moreover, the 2T3k model with fixation of $K_i/k_2$ was able to differentiate between lesions and NAWM, except for remyelinated lesions. This seems logical, as remyelinated lesions should have myelin densities close to the values of NAWM. Thus, the 2T3k model was considered to be the most appropriate model, as it produced more robust estimates than the 2T4k model. As the lesions were rather small ($0.22 \pm 0.80 \text{ mL}$), they most likely suffer from partial volume effects. Therefore, a correction of partial volume effects may lead to higher contrast between lesions and NAWM.

The simplified methods MLAIR2 and SUV provided estimates that correlated well with the 2T3k estimates and produced qualitatively good images, but the subject-dependent bias of the SUV when compared to 2T3k $K_i$ indicates that

| Method | Type of lesion | Lesion | NAWM | $U$   | $p$ value |
|--------|----------------|-------|------|-------|-----------|
| 2T3k + fixed $K_i/k_2$ | BH   | 0.072 ± 0.035 | 0.094 ± 0.039 | 6544 | < 0.001 |
| $K_i$ [mL min$^{-1}$ cm$^{-3}$] | DM   | 0.079 ± 0.038 | 0.108 ± 0.049 | 7785 | < 0.001 |
|       | PM   | 0.085 ± 0.042 | 0.106 ± 0.041 | 3075 | < 0.001 |
|       | RM   | 0.102 ± 0.054 | 0.118 ± 0.050 | 25   | 0.63     |
|       | SUV of 40–50 min [g cm$^{-3}$] | BH   | 1.65 ± 0.53 | 2.04 ± 0.52 | 8055 | < 0.001 |
|       | DM   | 1.74 ± 0.53 | 2.24 ± 0.60 | 9125 | < 0.001 |
|       | PM   | 1.82 ± 0.56 | 2.19 ± 0.57 | 3332 | < 0.001 |
|       | RM   | 1.91 ± 0.64 | 2.31 ± 0.67 | 35   | 0.21     |
|       | SUV of 50–60 min [g cm$^{-3}$] | BH   | 1.58 ± 0.44 | 1.97 ± 0.49 | 8048 | < 0.001 |
|       | DM   | 1.65 ± 0.51 | 2.13 ± 0.66 | 8940 | < 0.001 |
|       | PM   | 1.77 ± 0.54 | 2.10 ± 0.45 | 3299 | < 0.001 |
|       | RM   | 1.58 (± 0.68) | 1.92 (± 0.52) | 32   | 0.38     |

*2T3k + fixed $K_i/k_2$, the 2T3k model with a $K_i/k_2$ fixed to the whole brain WM $K_i/k_2$ value, 2T3k + fixed $K_i/k_2$ and $V_B$, the 2T3k model with both $K_i/k_2$ and $V_B$ fixed to the whole brain WM $K_i/k_2$ and $V_B$ value, $U$, the test statistic of the Mann–Whitney $U$ test.
SUV might be less suitable for inter-subject comparisons. Therefore, MLAIR2 could be used as an alternative for accurate and precise quantification, necessary for therapeutic drug development, whereas SUV could possibly be used for lesion identification. However, to substantiate the use of SUV for lesion identification, simulation studies have to be performed to assess the effect of confounders on SUV, as SUV estimates differ upon alterations of cardiovascular throughput, tracer clearance, and tracer excretion. Irrespective of those findings, MLAIR2 has the highest correlation with 2T3k model, is devoid of potential confounders regarding cardiovascular throughput, tracer clearance, and tracer excretion, and could therefore be used as an alternative quantification method for $^{[1]}$CMeDAS PET.

Current clinical research on myelin imaging with PET uses repurposed amyloid-beta PET tracers, such as $^{[1]}$CPIB and $^{[18]}$F]florbetaben, in combination with a reference tissue model for quantification [13, 25–29]. One of these studies found a decreased tracer uptake in NAWM of MS patients as compared to HC WM [27], whereas two other studies did not [13, 26]. With $^{[1]}$CMeDAS PET, we also did not find a decreased tracer uptake in NAWM of MS patients as compared to HC WM (data not shown). This would suggest that the myelin outside of MS lesions is preserved from MS pathology, or at least not severely enough affected to be detected. Furthermore, the PET studies with an amyloid tracer showed a decrease in the tracer uptake in MS lesions as compared with NAWM, which illustrates the potential of amyloid PET tracers for myelin imaging [13, 25–29]. $^{[1]}$C MeDAS PET seems to perform comparably with the amyloid PET tracers for assessing the total lesion burden. Although in previous PET studies with amyloid tracers decreases in tracer uptake in WML have been observed [13, 25, 27–29], no differentiation was made between lesion types with different myelin densities. In the present study, a reduced tracer uptake was observed in all types of lesions, except in remyelinated lesions. In addition, there was a relationship between $^{[1]}$CMeDAS uptake and degree of (expected) myelin density within lesions (BH < DM < PM < RM lesions; Table 6). The observed differences in tracer binding between lesions with different levels of myelin content support the specificity of $^{[1]}$CMeDAS as a myelin tracer. It also supports the potential use of $^{[1]}$CMeDAS binding as an accurate in vivo quantitative measure of myelin content. Furthermore, a longitudinal pilot study with $^{[1]}$CPIB already illustrated the potential of PET imaging for detecting temporal changes in myelin content [13], while this still remains to be investigated for $^{[1]}$CMeDAS PET. More detailed comparisons between tracers are difficult, because the published studies have used different patient populations of a highly heterogeneous disease and a different quantification method. While we used compartment modeling, the amyloid tracer studies did not acquire blood data and used therefore reference tissue methods. However, the use of a reference tissue method requires the absence of target expression in the reference region and stability of the $K_i/K_2$ across the whole brain. As MS lesions, in particular active lesions, can have alterations in the blood–brain barrier integrity, it is likely that reference tissue methods may be less suitable for analyzing MS data and therefore have not been investigated in this study. A prospective study directly comparing an amyloid tracer and $^{[1]}$CMeDAS in the same patients with the same scanning protocol and analysis method would enable a more thorough comparison of the tracers. Until such studies have been performed, no firm conclusion can be drawn regarding which tracer would be most specific and accurate.

In conclusion, $^{[1]}$CMeDAS PET can be used to differentiate between myelin densities of GM and WM and also between lesions that are radiologically categorized according to myelin density. The 2T3k model with fixed $K_i/K_2$ seems to be the preferred method for quantification, with $K_i$ being the most accurate parameter for estimating myelin density. Furthermore, MLAIR2 seems to be both qualitatively and quantitatively accurate and precise enough to be an alternative for the 2T3k model for $^{[1]}$CMeDAS PET quantification. Due to $^{[1]}$CMeDAS ability to estimate differences in myelin densities across lesions with different myelin densities, $^{[1]}$C MeDAS PET might be a potential quantitative biomarker for efficacy evaluation of remyelination therapies.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1007/s00259-022-05770-4.

Funding This study was supported by the Nederlandse organisatie voor gezondheidszonderzoek en zorginnovatie (ZonMW) with Stichting MS Research, grant number PTO-95105010.

Declarations

Conflict of interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis. Distribution of T cells, T cell subsets and In-positive macrophages in lesions of different ages. J Neuromed Immunol; 1983.

2. Ramagopalan PV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol; 2010. p. 727–39.

3. Morrison BM, Lee Y, Rothstein JD. Oligodendroglia: metabolic supporters of axons. Trends Cell Biol; 2013.

4. van der Weijden CWJ, Meilof JF, de Vries EFJ. PET Imaging in multiple sclerosis. In: Dierckx RAJO, Otto A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET SPECT Neuroil [Internet]. Cham: Springer International Publishing; 2021. p. 893–916. Available from: https://doi.org/10.1007/978-3-030-53168-3_33

5. van der Weijden CWJ, Garcia DV, Borra RJH, Thurner P, Meilof JF, van Laar P-J, et al. Myelin quantification with MRI: a systematic review of accuracy and reproducibility. Neuroimage [Internet]. 2021;226:117561. Available from: http://www.sciencedirect.com/science/article/pii/S10538119203010466

6. De Paula FD, Copray S, Sijbesma JWA, Willemsen ATM, Buchpigel CA, Dierckx RAJO, et al. PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [11C]MeDAS, [11C]CIC and [11C]PIB. Eur J Nucl Med Mol Imaging; 2014;41:995–1003.

7. de Paula FD, De Vries EFJ, Sijbesma JWA, Dierckx RAJO, Buchpigel CA, Copray S. PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: a comparison between [11C]CIC and [11C]MeDAS. Neuroimage. 2014;87:395–402.

8. Auvity S, Tonietti M, Caillé F, Bodini B, Bottlaender M, Tournier N, et al. Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. Eur J Nucl Med Mol Imaging; 2020.

9. Wu C, Wang C, Popescu DC, Zhu W, Somoza EA, Zhu J, et al. A novel PET marker for in vivo quantification of myelination. Bioorg Med Chem. 2010;18:8592–9.

10. Hagens MHJ, Golla SV, Wijburg MT, Yaqub M, Heijtel D, Steen-wijk MD, et al. In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F] DPA714 PET. J Neuroinflammation; 2018.

11. Hagens MHJ, Golla SSV, Janssen B, Vugs DJ, Beaino W, Windhorst AD, et al. The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in-man study. Eur J Nucl Med Mol Imaging; 2020.

12. Carvalho RHF, Real CC, Cinini S, Garcez AT, Duran FLS, Marques FLN, et al. [11C]PiB PET imaging can detect white and grey matter demyelination in a non-human primate model of progressive multiple sclerosis. Mult Scler Relat Disord Netherlands. 2019;35:108–15.

13. Bodini B, Veronese M, García-Lorenzo D, Battaglini M, Poirion E, Chardain A, et al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol; 2016.

14. Wu C, Wei J, Tian D, Feng Y, Miller RH, Wang Y. Molecular probes for imaging myelinated white matter in CNS. J Med Chem. 2008;51:6682–8.

15. Ridsdale RA, Beniac DR, Tompkins TA, Moscarello MA, Harauz G. Three-dimensional structure of myelin basic protein. J Biol Chem; 2002.

16. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol; 2018.

17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol; 2011.

18. Barkhof F, Bruck W, De Groot CIA, Bergers E, Huls Hof S, Geurts I, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance imaging appearance. Arch Neurol; 2003.

19. Sahraian MA, Radue EW, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand; 2010.

20. Ashburner J, Friston KJ. Unified segmentation. Neuroimage; 2005.

21. Hammers A, Al lom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp; 2003.

22. Kim SJ, Lee JS, Kim YK, Frost J, Wand G, McCauley ME, et al. Multiple linear analysis methods for the quantification of irreversibly binding radiotracers. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2008;28:1965–77.

23. Rostrup E, Knudsen GM, Law I, Holm S, Larsson HBW, Paulson OB. The relationship between cerebral blood flow and volume in humans. Neuroimage; 2005.

24. Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol; 2015.

25. Grech E, Veronese M, Bodini B, García-Lorenzo D, Battaglini M, Stankoff B, et al. Multimodal partial volume correction: application to [11C]PiB PET/MRI myelin imaging in multiple sclerosis. J Cereb Blood Flow Metab; 2017.

26. Zeydan B, Lowe VJ, Schwarz CG, Przybelski SA, Tosakulwong N, Zuk SM, et al. Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Mult Scler J; 2018.

27. Matias-Guiu JA, Cabrera-Martín MN, Matias-Guiu J, Oreja-Guevara C, Riola-Parada C, Moreno-Ramos T, et al. Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study. BMC Neurol; 2015.

28. Matias-Guiu JA, Cabrera-Martín MN, Cortés-Martínez A, Pytel V, Moreno-Ramos T, Oreja-Guevara C, et al. Amyloid PET in pseudotumoral multiple sclerosis. Mult Scler Relat Disord; 2017.

29. Pietroboni AM, Carandini T, Colombi A, Mercuro M, Ghezzi L, Giuliani G, et al. Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amylloid levels and brain volumes. Eur J Nucl Med Mol Imaging; 2019.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.